Table 2. Baseline Patient Characteristics after Propensity Score Matching (n=338).
| Variable | Early sADT (n=169) | Delayed sADT (n=169) | p value |
|---|---|---|---|
| Age (yr) | 66 (60–71) | 66 (62–70) | 0.208 |
| BMI (kg/m2) | 23.9 (22.1–26.1) | 24.1 (22.4–25.8) | 0.262 |
| Prostate volume measure by TRUS (mL) | 28.0 (23.0–38.0) | 28.0 (23.0–35.0) | 0.558 |
| PSA (ng/mL) | 9.5 (6.2–14.0) | 9.3 (6.4–13.0) | 0.882 |
| PSA (categorical) (ng/mL) | 0.841 | ||
| <20 | 155 (91.7) | 156 (92.3) | |
| ≥20 | 14 (8.3) | 13 (7.7) | |
| D'Amico risk classification | 0.530 | ||
| Low | 23 (13.6) | 22 (13.0) | |
| Intermediate | 66 (39.1) | 57 (33.7) | |
| High | 80 (47.3) | 90 (53.3) | |
| Pathologic T stage | 0.817 | ||
| Organ confined (T2) | 55 (32.5) | 57 (33.7) | |
| Non-organ confined (>T2) | 114 (67.5) | 112 (66.3) | |
| Pathologic Gleason score | 0.790 | ||
| <8 | 134 (79.3) | 132 (78.1) | |
| ≥8 | 35 (20.7) | 37 (21.9) | |
| Positive surgical margin | 117 (69.2) | 111 (65.7) | 0.486 |
| PSA at sADT (ng/mL) | 0.12 (0.11–0.16) | 0.42 (0.27–1.10) | 0.010 |
| Type of ADT | 0.115 | ||
| LHRH agonist or antagonist with anti-androgens | 90 (53.3) | 101 (59.8) | |
| LHRH agonist or antagonist only | 57 (33.7) | 40 (23.7) | |
| Anti-androgens only | 22 (13.0) | 28 (16.6) | |
| PSA doubling time (month) | 3.4 (1.9–6.1) | 3.6 (1.7–7.9) | 0.572 |
| Salvage radiotherapy | 26 (15.4) | 60 (35.5) | <0.001 |
| PSA >0.2 ng/mL after sADT | 45 (26.8) | 96 (57.1) | <0.001 |
BMI, body mass index; LHRH, luteinizing hormone-releasing hormone; PSA, prostate-specific antigen; sADT, salvage androgen deprivation therapy; TRUS, transrectal ultrasonography.
Data are expressed as median (interquartile range) or n (%).